In: NEOPLASMA, vol. 62, no. 3
P. Tesarova - M. Cabinakova - V. Mikulova - T. Zima - M. Kalousova
Detaily:
Rok, strany: 2015, 353 - 364
O článku:
Receptor for advanced glycation end products (RAGE) plays a central role in the regulation of tissue homeostasis, regeneration and resolution of inflammation, but under pathological conditions RAGE-mediated pathways may induce diminished apoptosis, but enhanced autophagy and cell necrosis. These mechanisms may contribute to malignant transformation, cancer progression and metastases. Soluble RAGE may bind natural RAGE ligands and counteract some of the RAGE-mediated effects. Activation of RAGE was demonstrated in different types of cancer (including colon, pancreatic and breast cancer). Expression of RAGE and serum levels of soluble RAGE may serve as cancer biomarkers and strategies aimed at interfering with RAGE signaling might be promising anticancer drugs. Keywords: RAGE, cancer, HMGB1, S100 proteins
Ako citovať:
ISO 690:
Tesarova, P., Cabinakova, M., Mikulova, V., Zima, T., Kalousova, M. 2015. RAGE and its ligands in cancer – culprits, biomarkers, or therapeutic targets?. In NEOPLASMA, vol. 62, no.3, pp. 353-364. 0028-2685.
APA:
Tesarova, P., Cabinakova, M., Mikulova, V., Zima, T., Kalousova, M. (2015). RAGE and its ligands in cancer – culprits, biomarkers, or therapeutic targets?. NEOPLASMA, 62(3), 353-364. 0028-2685.